| 2013 | | A combination of cilostazol and Ginkgo biloba extract protects against cisplatin-induced Cochleo-vestibular dysfunction by inhibiting the mitochondrial apoptotic and ERK pathways. | 김유석, 임혜진, 정연훈 |
| 2014 | | A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. | 탁승제 |
| 2016 | | Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database | 임홍석 |
| 2016 | | Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study | 윤명호 |
| 2018 | | Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial | 박래웅, 윤덕용, 이성준, 이진수, 최문희, 홍지만 |
| 1999 | | Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist. | 이수환, 정이숙 |
| 2017 | | Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique | 이성준, 이진수, 최문희, 홍지만 |
| 2005 | | Comparison of cilostazol and clopidogrel after successful coronary stenting. | 강수진 |
| 2017 | | Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study | 이진수 |
| 2013 | | Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial. | 용석우 |
| 2018 | | Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study | 박인휘 |
| 2012 | | Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies | 신준한 |
| 2015 | | Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy. | 신준한 |
| 2016 | | Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension | 강대용 |
| 2016 | | Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: K-MetS Study | 강대용 |
| 2019 | | Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study | 박래웅, 윤덕용 |
| 1998 | | Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. | 문창현, 백은주, 이수환, 이희주, 정이숙 |
| 1999 | | Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog. | 이수환, 정이숙 |
| 2017 | | The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia | 탁승제 |
| 2015 | | TM-25659-Induced Activation of FGF21 Level Decreases Insulin Resistance and Inflammation in Skeletal Muscle via GCN2 Pathways. | 강엽, 이관우, 전자영, 최성이 |
